Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -78.16% is 54% below its 5-year average of -50.80%, around the middle of its 5-year range (-130.84%–-11.57%).
229.86% below its 12-month average of -23.70%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -25.08%.
RETURN ON ASSETS (ROA)
-78.16%
RETURN ON ASSETS (ROA) AVG TTM
-23.70%
RETURN ON ASSETS (ROA) AVG 3Y
-68.26%
RETURN ON ASSETS (ROA) AVG 5Y
-50.80%
RETURN ON ASSETS (ROA) AVG 10Y
-71.87%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-229.86%
CURRENT VS 3Y AVG
-14.51%
CURRENT VS 5Y AVG
-53.84%
CURRENT VS 10Y AVG
-8.75%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-142.43%
vs the sector median at left
Eledon Pharmaceuticals, Inc.
Market Cap
$189.50M
Return on Assets (ROA)
-78.16%
TTM Avg
-23.70%
3Y Avg
-68.26%
5Y Avg
-50.80%
Market Cap
$192.29M
Return on Assets (ROA)
-13.31%
TTM Avg
-10.55%
3Y Avg
-23.05%
5Y Avg
-15.01%
Market Cap
$193.27M
Return on Assets (ROA)
-81.22%
TTM Avg
-42.98%
3Y Avg
-45.19%
5Y Avg
-41.10%
Market Cap
$184.94M
Return on Assets (ROA)
-44.41%
TTM Avg
-56.25%
3Y Avg
-49.77%
5Y Avg
-92.23%
Market Cap
$183.69M
Return on Assets (ROA)
-38.62%
TTM Avg
-32.73%
3Y Avg
-28.05%
5Y Avg
-37.08%
Market Cap
$183.55M
Return on Assets (ROA)
-17.38%
TTM Avg
-167.34%
3Y Avg
-136.62%
5Y Avg
-286.91%
Market Cap
$181.30M
Return on Assets (ROA)
47.31%
TTM Avg
7.73%
3Y Avg
-1.35%
5Y Avg
-4.55%
Market Cap
$199.87M
Return on Assets (ROA)
-287.29%
TTM Avg
-188.15%
3Y Avg
-127.49%
5Y Avg
-100.14%
Market Cap
$178.83M
Return on Assets (ROA)
-79.26%
TTM Avg
-73.67%
3Y Avg
-58.36%
5Y Avg
-102.57%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | $189.50M | -78.16% | -23.70% | -68.26% | -50.80% |
| RxSight, Inc. (RXST)vs › | $192.29M | -13.31% | -10.55% | -23.05% | -15.01% |
| Zentalis Pharmaceuticals, Inc. (ZNTL)vs › | $193.27M | -81.22% | -42.98% | -45.19% | -41.10% |
| AN2 Therapeutics, Inc. (ANTX)vs › | $184.94M | -44.41% | -56.25% | -49.77% | -92.23% |
| Compass Therapeutics, Inc. (CMPX)vs › | $183.69M | -38.62% | -32.73% | -28.05% | -37.08% |
| Canton Strategic Holdings Inc (CNTN)vs › | $183.55M | -17.38% | -167.34% | -136.62% | -286.91% |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $181.30M | 47.31% | 7.73% | -1.35% | -4.55% |
| Surrozen, Inc. (SRZN)vs › | $199.87M | -287.29% | -188.15% | -127.49% | -100.14% |
| Yarrow Bioscience Inc (YARW)vs › | $178.83M | -79.26% | -73.67% | -58.36% | -102.57% |
| Alector, Inc. (ALEC)vs › | $200.40M | -58.10% | -37.08% | -28.02% | -25.91% |
ROA
-78.2%
ROE
-136.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -26.99% |
| 2024-12-31 | -20.40% |
| 2023-12-31 | -130.84% |
| 2022-12-31 | -94.80% |
| 2021-12-31 | -20.23% |
| 2020-12-31 | -11.57% |
| 2019-12-31 | -146.47% |
| 2018-12-31 | -82.61% |
| 2017-12-31 | -62.78% |
| 2016-12-31 | -127.55% |
| 2015-12-31 | -66.33% |
| 2014-12-31 | -21.62% |
| 2013-12-31 | -48.70% |
| 2012-12-31 | -80.66% |
